Long-Term Outcomes of Patients with IgA Nephropathy Categorized by the International IgAN Risk Prediction Tool and by the Degree of Hematuria at Diagnosis | Zendy

Robin Ebbestad | Zendy; Mazdak Sanaei Nurmi | Zendy; Sigrid Lundberg | Zendy

Open Access

Long-Term Outcomes of Patients with IgA Nephropathy Categorized by the International IgAN Risk Prediction Tool and by the Degree of Hematuria at Diagnosis

Author(s) -

Robin Ebbestad,

Mazdak Sanaei Nurmi,

Sigrid Lundberg

Publication year - 2022

Publication title -

the nephron journals/nephron journals

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.951

H-Index - 72

eISSN - 2235-3186

pISSN - 1660-8151

DOI - 10.1159/000525001

Subject(s) - microhematuria , medicine , nephropathy , renal function , cohort , kidney disease , nephrology , microalbuminuria , urology , proteinuria , gastroenterology , kidney , endocrinology , diabetes mellitus

Within 30 years, 20-50% of IgA nephropathy (IgAN) patients progress to end-stage kidney disease (ESKD). Identifying these patients can be difficult since renal function may deteriorate after being stable for years. The International IgAN Risk Prediction tool (IgAN-RPT) combines histologic lesions and clinical risk factors to predict renal outcome up to 5 or 7 years of follow-up. The clinical value beyond 7 years is unknown and microhematuria data has not been assessed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research